InvestorsHub Logo
Followers 20
Posts 1184
Boards Moderated 0
Alias Born 05/06/2014

Re: BioSpecialist post# 16320

Friday, 06/10/2016 2:37:41 PM

Friday, June 10, 2016 2:37:41 PM

Post# of 38634
Actually their fiscal year ends November 30... so even June would be considered 3rd quarter

Best forget which quarter and go by June/July timeframe.

I think what is far more important than the filing is the FDA acceptance of the NDA which is usually within 30 days after filing, and issuance at that time the PDUFA date... which should be for 6 months from date of filing since they are fast-tracked.

Acceptance of the NDA pretty much cements that they do NOT indeed need to do a phase 3 - which saves about 20 million $, and even more importantly around 2 years of time,

I think once that is known for sure... we'll see a partnership announced that takes all that into consideration.

I believe it will in fact be accepted and I am then expecting a $400 million total package -

$40 million up front + 20% royalty payments
$60 million on FDA approval
$100 million on $1 Billion aggregate sales milestone
$200 million on $3 billion aggregate sales milestone

or possibly 25% to 30% royalty payments on a $250 to $300 million total package.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y